Shares of Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharmaceutical company, are currently up over 450% at $25, following an agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, a late-stage Wilson disease drug candidate.
Alexion, AstraZeneca Rare Disease is a research group within AstraZeneca (AZN) focused on rare diseases. It was created in 2021 after AstraZeneca acquired Alexion Pharmaceuticals Inc. for $39 billion or $175 per share.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.